88422-83-7

Basic information

• Product Name: 2-((3,4-dihydroisoquinolin-1-yl)methyl)isoindoline-1,3-dione
• Synonyms: 2-((3,4-dihydroisoquinolin-1-yl)methyl)isoindoline-1,3-dione;1H-Isoindole-1,3(2H)-dione, 2-[(3,4-dihydro-1-isoquinolinyl)methyl]-;2-((3,4-dihydroisoquinolin-1-yl)methyl)isoindoline-1,3-dione(WXC06855)
• CAS NO: 88422-83-7
• Molecular Formula: C₁₈H₁₄N₂O₂
• Molecular Weight: 290.31596
• Mol File: 88422-83-7.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-((3,4-dihydroisoquinolin-1-yl)methyl)isoindoline-1,3-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 2-((3,4-dihydroisoquinolin-1-yl)methyl)isoindoline-1,3-dione(88422-83-7)
• EPA Substance Registry System: 2-((3,4-dihydroisoquinolin-1-yl)methyl)isoindoline-1,3-dione(88422-83-7)

Safety Data

• Hazardous Substances Data: 88422-83-7(Hazardous Substances Data)

Usage

Type

Chemical compound

Development

Synthetic compound

Pharmacological properties

Potential anti-inflammatory and analgesic properties

Therapeutic potential

Potential candidate for the development of new pharmaceuticals

Unique structure

Interesting for further research and potential therapeutic applications

Investigation

Has been studied for its potential as a therapeutic agent

Upstream product

• 85-44-9 phthalic anhydride 
• 13156-95-1 2-chloro-N-phenethylacetamide 
• 4702-13-0 N-phthaloylglycine 
• 64-04-0 phenethylamine 
• 6780-38-7 N-phthaloylglycine chloride 
• 88422-74-6 2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-N-(2-phenylethyl)acetamide 

Downstream Products

• 908249-20-7 2-[(1S)-1,2,3,4-tetrahydroisoquinolin-1-ylmethyl]-2,3-dihydro-1H-isoindole-1,3-dione 
• 1432065-37-6 benzyl-(1S,2R)-2-[(1S)-1-[(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)methyl]-1,2,3,4-tetrahydroisoquinoline-2-carbonyl]cyclohexane-1-carboxylate 
• 1432500-66-7 (1S,2R)-2-[(1S)-1-[(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-carbonyl]cyclohexane-1-carboxylic acid 
• 1432065-33-2 C₂₆H₂₆N₂O₅ 
• 1432065-34-3 C₂₆H₂₆N₂O₅ 
• 1432065-35-4 C₂₆H₂₆N₂O₅ 
• 310451-86-6 2-(1,2,3,4-tetrahydro-1-isoquinolinylmethyl)-1H-isoindole-1,3(2H)-dione 
• 60567-63-7 (1,2,3,4-tetrahydroisoquinoline-1-yl)methylamine dihydrochloride 

Relevant articles and documents

Tetrazanbigen Derivatives as Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Partial Agonists: Design, Synthesis, Structure-Activity Relationship, and Anticancer Activities

Tetrazanbigen (TNBG) is a novel sterol isoquinoline derivative with poor water solubility and moderate inhibitory effects on human cancer cell lines via lipoapoptosis induction. Herein, we developed a series of novel TNBG analogues with improved water sol

HETEROCYCLIC COMPOUNDS AND USE THEREOF

Disclosed are compounds of formula (I) below or pharmaceutically acceptable salts thereof: in which each of variables R1-R6, L, m, and n is defined herein. Also disclosed are a method for treating an opioid receptor-associated condit

A Comparative Assessment Study of Known Small-Molecule Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular Activity

Inhibiting the protein-protein interaction (PPI) between the transcription factor Nrf2 and its repressor protein Keap1 has emerged as a promising strategy to target oxidative stress in diseases, including central nervous system (CNS) disorders. Numerous non-covalent small-molecule Keap1-Nrf2 PPI inhibitors have been reported to date, but many feature suboptimal physicochemical properties for permeating the blood-brain barrier, while others contain problematic structural moieties. Here, we present the first side-by-side assessment of all reported Keap1-Nrf2 PPI inhibitor classes using fluorescence polarization, thermal shift assay, and surface plasmon resonance - and further evaluate the compounds in an NQO1 induction cell assay and in counter tests for nonspecific activities. Surprisingly, half of the compounds were inactive or deviated substantially from reported activities, while we confirm the cross-assay activities for others. Through this study, we have identified the most promising Keap1-Nrf2 inhibitors that can serve as pharmacological probes or starting points for developing CNS-active Keap1 inhibitors.